Gelonghui, April 23丨Huluwa (605199.SH) announced that the company recently received the “Drug Registration Certificate” for terbutaline sulfate nebulized inhalation solution approved and issued by the State Drug Administration. Terbutaline sulfate nebulized inhalation solution is used to relieve bronchospasm associated with bronchial asthma, chronic bronchitis, emphysema, and other lung diseases. Suitable for adults and children.
葫芦娃(605199.SH)：获得硫酸特布他林雾化吸入用溶液药品注册证书
Huluwa (605199.SH): Obtained drug registration certificate for terbutaline sulfate nebulized inhalation solution
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.